PatientsVille.com Logo

UNEVALUABLE EVENT and Potassium

PatientsVille

UNEVALUABLE EVENT Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for UNEVALUABLE EVENT

UNEVALUABLE EVENT treatment research studies

Potassium clinical trials, surveys and public health registries


Find Drug Side Effect reports



Potassium Side Effects

Hyperkalaemia (64)
Nausea (46)
Pain (45)
Dyspnoea (43)
Dizziness (42)
Asthenia (41)
Fatigue (37)
Cardiac Arrest (34)
Diarrhoea (33)
Completed Suicide (29)
Vomiting (28)
Renal Failure (28)
Oedema Peripheral (27)
Chest Pain (26)
Anxiety (26)
Pain In Extremity (25)
Muscle Spasms (25)
Fall (24)
Death (24)
Pyrexia (23)
Headache (22)
Weight Decreased (22)
Hypersensitivity (21)
Blood Potassium Increased (21)
Renal Failure Acute (20)
Arthralgia (20)
Injury (19)
Abdominal Pain (19)
Cough (19)
Hypotension (19)
Pneumonia (18)
Dehydration (18)
Abdominal Pain Upper (18)
Back Pain (18)
Confusional State (17)
Anaemia (17)
Depression (17)
Hypertension (17)
Overdose (17)
Malaise (17)
Cerebrovascular Accident (16)
Hypokalaemia (16)
Rash (15)
Respiratory Failure (15)
Injection Site Pain (15)
Cardiac Failure Congestive (15)
Blood Potassium Decreased (14)
Feeling Abnormal (14)
Product Quality Issue (14)
Thrombocytopenia (14)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

BLOOD rEPORT TOO HIGH 6.8

High potassium what are the side effects

I have takesn ecoclav dua for thorate infection what is harm

I want to know whether losartan casuse erectile disfunction ( E D )

Dear Medwrench, I want to share this information with you in hopes of saving someone else the pain my wife is suffering. An uncommon event happened to my wife during her Radiofrequency Ablation. My only purpose is to

I experienced a near death medical event (PE) and began acting without any care about my own health by seeking and attaing a full-time job without declaring my illness less than a month after leaving hospital, I left the job due to heart pains within

I had 14 crushed zimovave taken ini f=juice , ave aslos otaken i4 ibrifrnin = some anti depprent medicationand bit of alkahol event some nynetool ,probaoly want to die as i don not have leave before itell my mother i loved much but icantsta

I started with 50 mg back in jan 2008 and that seemed to keep what was then a once a month sometimes less event of AF the AF seemed to groing quite regular and so i reluctantly moved to 100 then during 2010 it was at 200mg. now in 2010 it get the AF

I used zeffix for a minimum period of 24 months because iwas confirmedHBsag positive. While on the prescription, i notice a lot of forgetfulness in me. b4 then i could remember an event that happened with every little details. But

I was prescribed Cardizem and Entrophen on March 16, 2011 at the Cardiology Institute in Montreal after an event. 10 days later my aryhthmic heart beats are ongoing and even more frequent. My morning blood pressure is 100/74 and my pulse is 67, but w

I went for an MRI with contrast. When the gadalinium was administered, I experienced a transient global amnesia event. I had to be taken to an ER and was admitted to the hospital. Docs insisted the gadalinium would not t

I went reluctantly against my will and now I am paying the 'heavy' price for my indicision... that other people had eventually made for me... thus suffering, now, from' the unintended consequences' of this terrible event. Ever since that fateful d

Male got zostavax vaccine age 60. Three months later diagnosed with Cutaneous Lupus and sjogren's symdrome, adverse event from zostavax. Continues to suffer, life long, with lupus and sjogrens.

My mom is in the hospital for bowel surgery, and it has been since thursday that they administerd the anesthsia, and she still had diplopia...she had a hypotensive event in the post up room, and now I read that it can cause diplopia, is that true, an

UNEVALUABLE EVENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Bioavailability of Potassium From Potatoes and Potassium Gluconate
Conditions: Potassium Bioavailability;   Blood Pressure
Interventions: Dietary Supplement: Placebo control;   Dietary Supplement: Low dose Potassium gluconate;   Dietary Supplement: Medium dose Potassium gluconate;   Dietary Supplement: High dose Potassium gluconate;   Dietary Supplement: Low dose potato;   Dietary Supplement: Medium dose potato;   Dietary Supplement: High dose potato;   Dietary Supplement: High dose French fries;   Dietary Supplement: Basal diet control
Outcome Measures: Bioavailability of Potassium;   Blood Pressure Response to Potassium
2 Not yet recruiting Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions
Condition: Hyperkalemia
Intervention: Behavioral: decision support in Potassium-inc. drug-drug-interactions
Outcome Measures: Impact on serum Potassium monitoring during Potassium-increasing drug-drug-interactions;   Frequency of hyperkalemia during Potassium-increasing drug-drug-interactions;   Frequency of Potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia;   Frequency of transfers to the ICU during Potassium-increasing drug-drug-interactions in function of the serum Potassium level;   Frequency of death during Potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia;   Change in frequency distribution of serum Potassium monitoring intervals;   Response of physicians to the computer-based alerts and reminders
3 Recruiting Comparison of Enteral Versus Intravenous Potassium Supplementation
Condition: Acute Hypokalemia
Interventions: Drug: Intravenous Potassium chloride;   Drug: Oral Potassium chloride
Outcome Measures: The efficacy EPR and IVPR for treatment of hypokalemia (measured as change in serum Potassium levels in milliequivalent/liter (mEq/L) after Potassium replacement;   Comparison of adverse effects after EPR and IVPR.;   Comparison of number of dose/s required to achieve resolution of hypokalemia;   Efficacy of EPR and IVPR for various degrees of severity of hypokalemia for each episode of hypokalemia
4 Unknown  Effect of Rapid Transfusion With Fluid Management System (FMS) on Plasma Potassium in Liver Transplantation Recipients
Condition: Condition Requiring Rapid Transfusion During Liver Transplantation Surgery
Intervention:
Outcome Measures: Potassium concentration in the Fluid Management System (FMS) reservoir;   plasma Potassium of the patient
5 Not yet recruiting Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature
Condition: Nephrocalcinosis
Interventions: Drug: Potassium Citrate;   Drug: Placebo
Outcome Measures: incidence of nephrocalcinosis in extremely preterm infants;   Determine whether the administration of Potassium citrate in extreme premature decreases neonates the levels of calcium and calcium / creatinine ratio in urine in each of the branches of treatment at 38-40 weeks;   To determine whether administration of Potassium citrate improves the levels of urinary phosphorus, Potassium, sodium, citrate, creatinine, oxalate, ratio citrate / calcium , and ph value;   Determine whether the administration of Potassium citrate improves the plasma levels of sodium, Potassium, creatinine, calcium, and ph value.;   To determine the incidence of adverse events and serious adverse events related to study treatment.
6 Unknown  Effects of Potassium Salts on Blood Pressure and Target Organ Damage
Condition: Hypertension
Intervention: Behavioral: Potassium supplementation
Outcome Measures: Blood pressure and markers of target organ damage and bone health at 4 weeks of Potassium supplementation.;   Comparisons among different treatments in blood pressure and markers of target organ damage and bone health.
7 Recruiting Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Condition: Hypertension
Interventions: Drug: Potassium chloride powder;   Drug: Potassium citrate powder;   Drug: Potassium magnesium citrate powder;   Drug: Placebo
Outcome Measures: 24-hour blood pressure;   Office blood pressure;   Serum C-terminal telopeptide (CTX);   24-hour urinary calcium;   Carotid to femoral pulse wave velocity;   Central aortic blood pressure
8 Recruiting Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter
Conditions: Atrial Fibrillation;   Atrial Flutter;   Potassium;   Cardioversion
Intervention: Drug: Potassium chloride
Outcome Measures: Cardioversion (time and percentage);   Atrial fibrillation at 3 months follow up visit and during 72 hours ECG-monitoring period.
9 Recruiting Combined Dietary Education of Low Sodium and High Potassium Consumption
Conditions: Prehypertension;   Hypertension
Interventions: Behavioral: dietary education of low sodium and high Potassium consumption;   Behavioral: dietary education of low sodium consumption only
Outcome Measures: changes of 24-hour ambulatory systolic and diastolic blood pressure;   changes of 24-hour urine sodium and Potassium excretion;   changes of renin and aldosterone
10 Not yet recruiting Investigating a New Way of Giving Medicine to Newborn and Preterm Babies
Conditions: Hypophosphataemia;   Osteopenia of Prematurity
Interventions: Drug: Oral thin film therapy (Potassium acid phosphate oral thin films);   Drug: Standard therapy (Potassium acid phosphate oral solution)
Outcome Measures: Serum phosphate;   Age-appropriateness
11 Unknown  Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone
Condition: Acute Coronary Syndrome
Interventions: Drug: glucose insulin Potassium;   Drug: GIK and intensive insulin therapy
Outcome Measures: 30 days mortality, reinfarction, urgent coronary revascularisation, and stroke.;   Severe dysrhythmias, acute left ventricular failure with ejection fraction<45%, change of serum B-type natriuretic peptide (BNP), serum troponin, and platelet factor activator (PFA-100) within 24 hours after the start of protocol treatment.
12 Recruiting Potassium Citrate Supplementation vs. Dietary Counseling
Condition: Kidney Stone
Interventions: Dietary Supplement: Potassium Citrate Supplementation;   Other: Dietary Education
Outcome Measure: Change in 24-hour urine parameters
13 Recruiting Musculoskeletal Effects of Bicarbonate
Conditions: Age-related Bone Loss;   Age Related Muscle Loss;   Falls;   Fractures
Interventions: Dietary Supplement: Potassium bicarbonate;   Other: placebo
Outcome Measures: The primary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary N-telopeptide/creatinine ratio;   The secondary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary nitrogen/creatinine ratio
14 Recruiting Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin;   Drug: Oxaliplatin; Capecitabine
Outcome Measures: Disease-free survival(DFS);   Objective response rate (ORR);   Disease control rate (DCR);   Down staging rate;   Overall survival (OS);   Adverse events;   R0-resection rate
15 Unknown  Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum
Condition: Molluscum Contagiosum
Interventions: Drug: Hydroxide Potassium;   Drug: Placebo
Outcome Measure: Efficacy (diseappearance of lesions)
16 Unknown  The Effects of Potassium Citrate on Bone Metabolism
Conditions: Bone Diseases, Metabolic;   Osteoporosis, Postmenopausal
Intervention: Drug: Potassium citrate
Outcome Measures: Bone turnover markers;   Bone Density by DEXA
17 Recruiting Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental Hypersensitivity
Condition: Dentin Sensitivity
Intervention: Device: Potassium oxalate
Outcome Measure: Dentin sensitivity
18 Recruiting Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
Conditions: Glomerulonephritis;   Proteinuria
Interventions: Drug: Shenyankangfu tablets;   Drug: Losartan Potassium 50mg;   Drug: Shenyankangfu tablets and Losartan Potassium 50mg;   Drug: Shenyankangfu tablets and Losartan Potassium 100mg;   Drug: Losartan Potassium 100mg
Outcome Measures: changes of 24 hours proteinuria after the treatment;   changes of serum creatinine after treatment;   changes of eGFR after the treatment;   changes of Traditional Chinese Medicine syndrome scores after the treatment
19 Recruiting Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment
Condition: Cough
Interventions: Drug: Syrup of oxomemazine, guaifenesin and Potassium iodate;   Drug: Syrup of guaifenesin
Outcome Measures: Reduction/improvement of cough symptoms;   Tolerance
20 Unknown  Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns
Condition: Healthy Infants
Intervention:
Outcome Measure: Potassium Measurements